Surgery
Volume 146, Issue 2 , Pages 316-324, August 2009

Daptomycin for the treatment of surgical site infections

  • Ronald S. Chamberlain, MD, MPA

      Affiliations

    • Department of Surgery, St Barnabas Medical Center, Livingston, NJ
    • Corresponding Author InformationReprint requests: Ronald S. Chamberlain, MD, MPA, Department of Surgery, St Barnabas Medical Center, Department of Surgery, 94 Old Short Hills Road, Livingston, NJ 07039.
    • ,
  • Darren L. Culshaw, PharmD

      Affiliations

    • Cubist Pharmaceuticals, Inc., Lexington, MA
    • ,
  • Brian J. Donovan, PharmD

      Affiliations

    • Cubist Pharmaceuticals, Inc., Lexington, MA
    • ,
  • Kenneth C. Lamp, PharmD

      Affiliations

    • Cubist Pharmaceuticals, Inc., Lexington, MA

Accepted 20 March 2009.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 An abstract on this subject was accepted for a 3-minute oral presentation at 4th Annual Academic Surgical Congress, Fort Myers, Florida, February 3–6, 2009.

 Dr Chamberlain is associated with Cubist (speaker's bureau), Ethicon (scientific advisor), Pfizer (speaker's bureau), and Wyeth (speaker's bureau). Messrs Culshaw, Donovan, and Lamp are employees of Cubist.

PII: S0039-6060(09)00271-2

doi:10.1016/j.surg.2009.03.037

Surgery
Volume 146, Issue 2 , Pages 316-324, August 2009

Article Tools